First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.

Single Agent ◽

Wild Type ◽

First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study

Annals of Oncology ◽

10.1093/annonc/mdy149.015 ◽

2018 ◽

Vol 29 ◽

pp. v106

Author(s):

F. Pietrantonio ◽

F. Morano ◽

S. Corallo ◽

A. Raimondi ◽

F. Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Maintenance Therapy ◽

Single Agent ◽

Wild Type ◽

First-Line Panitumumab Plus FOLFOX-4 Followed by Maintenance Therapy with Single-Agent Panitumumab or Panitumumab Plus 5-FU/LV in Patients with RAS Wild-Type Metastatic Colorectal Cancer: The Valentino Study

SSRN Electronic Journal ◽

10.2139/ssrn.3254485 ◽

2018 ◽

Author(s):

Filippo Pietrantonio ◽

Federica Morano ◽

Salvatore Corallo ◽

Rosalba Miceli ◽

Sara Lonardi ◽

...

Keyword(s):

Colorectal Cancer ◽

Maintenance Therapy ◽

Single Agent ◽

Wild Type ◽

First-line FOLFOX-4 plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients (pts) with RAS wild-type, metastatic colorectal cancer (mCRC): The VALENTINO study.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps3634 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS3634-TPS3634

Author(s):

Filippo Pietrantonio ◽

Marta Caporale ◽

Rosa Berenato ◽

Sara Lonardi ◽

Roberto Murialdo ◽

...

Keyword(s):

Colorectal Cancer ◽

Maintenance Therapy ◽

Single Agent ◽

Wild Type ◽

Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study

Annals of Oncology ◽

10.1093/annonc/mdy424.023 ◽

2018 ◽

Vol 29 ◽

pp. viii716 ◽

Cited By ~ 1

Author(s):

F. Morano ◽

S. Corallo ◽

M. Di Bartolomeo ◽

S. Lonardi ◽

C. Cremolini ◽

...

Keyword(s):

Colorectal Cancer ◽

Maintenance Therapy ◽

Single Agent ◽

Wild Type ◽

First Line ◽

Selection Of

First‐Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single‐Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

The Oncologist ◽

10.1634/theoncologist.2011-0249 ◽

2012 ◽

Vol 17 (1) ◽

pp. 15-25 ◽

Cited By ~ 140

Author(s):

Eduardo Díaz‐Rubio ◽

Auxiliadora Gómez‐España ◽

Bartomeu Massutí ◽

Javier Sastre ◽

Albert Abad ◽

...

Keyword(s):

Colorectal Cancer ◽

Maintenance Therapy ◽

Single Agent ◽

Phase Iii ◽

Faculty Opinions recommendation of First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13945972.15401076 ◽

2012 ◽

Author(s):

Werner Scheithauer

Keyword(s):

Colorectal Cancer ◽

Maintenance Therapy ◽

Single Agent ◽

Phase Iii ◽

Phase Ii Study of First-Line Mfolfox Plus Cetuximab (C) for 8 Cycles Followed By Mfolfox Plus C or Single Agent (S/A) C As Maintenance Therapy in Patients (P) with Metastatic Colorectal Cancer (Mcrc): the Macro-2 Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [Ttd])

Annals of Oncology ◽

10.1093/annonc/mdu333.3 ◽

2014 ◽

Vol 25 ◽

pp. iv168 ◽

Cited By ~ 11

Author(s):

P. García Alfonso ◽

M. Benavides ◽

A. Sánchez Ruiz ◽

C. Guillen-Ponce ◽

M.J. Safont ◽

...

Keyword(s):

Colorectal Cancer ◽

Maintenance Therapy ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Cooperative Group ◽

A phase II trial of mFOLFOX-bevacizumab (bev) followed by single-agent axitinib (ax) as maintenance therapy for patients (pts) with first-line metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e14673 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e14673-e14673 ◽

Cited By ~ 1

Author(s):

Mathew John Joseph ◽

Kirk Barnes ◽

Ronald Blachly ◽

Michel E. Kuzur ◽

Johanna C. Bendell

Keyword(s):

Colorectal Cancer ◽

Maintenance Therapy ◽

Phase Ii ◽

Phase Ii Trial ◽

Single Agent ◽

A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer

Cancer Investigation ◽

10.1080/07357907.2017.1310221 ◽

2017 ◽

Vol 35 (6) ◽

pp. 386-392 ◽

Cited By ~ 2

Author(s):

Johanna C. Bendell ◽

Mathew Joseph ◽

Kirk Barnes ◽

Mark Mainwaring ◽

Dianna Shipley ◽

...

Keyword(s):

Colorectal Cancer ◽

Maintenance Therapy ◽

Single Agent ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

First Line Treatment

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours

European Journal of Cancer ◽

10.1016/j.ejca.2015.04.013 ◽

2015 ◽

Vol 51 (11) ◽

pp. 1371-1380 ◽

Cited By ~ 30

Author(s):

J. Sastre ◽

B. Massuti ◽

G. Pulido ◽

C. Guillén-Ponce ◽

M. Benavides ◽

...

Keyword(s):

Colorectal Cancer ◽

Prognostic Factors ◽

Elderly Patients ◽

Frail Elderly ◽

Phase Ii Study ◽

Single Agent ◽

Cooperative Group ◽

Wild Type ◽